CSAM Announces Agreement to Acquire Databyrån AB

On 27 September 2023, CSAM Health Group AS changed its name to Omda AS. For articles on historical events such as transactions, financial results etc. we will not retroactively change the name.
___

The agreed Acquisition of ProSang company strengthens CSAM’s position as the leading provider of specialized solutions in the Nordic eHealth Market.

OSLO, Norway – CSAM announced today that it has signed an agreement to acquire the Swedish company Databyrån AB, makers of ProSang. With this acquisition, CSAM adds an exciting new specialized product area to its leading portfolio of eHealth niche solutions in the Nordics.

ProSang is an advanced Laboratory Information Management System (LIMS) that simplifies the entire management of blood – from blood donor call–up to transfusion. Since its inception in 1965, Databyrån AB has grown to achieve a leading market position within the Nordics. Today, more than 180 blood centres and several clinical immunology and transplantation departments use ProSang.

– Databyrån AB has established loyal and satisfied user groups in many countries, and I am incredibly impressed by what their team has accomplished with ProSang, said Sverre Flatby, CEO of CSAM. – We are proud that the owners of ProSang have chosen to join the CSAM team, and we look forward to welcoming them and working together to secure further growth and export.

– To continue the journey towards our ambitious vision, I am confident that CSAM is the best home for ProSang, Databyrån’s employees, and our customers, said Daniel Wiman, Chairman of Databyrån AB. – Today’s agreement ensures that our employees can continue working as a specialized team, while benefitting from the shared services CSAM provides, and strengthening our sales and development capabilities.

The Databyrån AB transaction reinforces CSAM’s focus on accelerating growth through strategic acquisitions, strengthening the company’s portfolio of niche products and their leadership position in the Nordic eHealth market.

About CSAM 

CSAM is a privately-owned eHealth company delivering software solutions that enable healthcare providers to access relevant clinical information at the point of care. CSAM’s headquarters are located in Oslo, Norway, with local offices in Stockholm, Gothenburg, Helsinki, Oulu, Tampere, and London. The company also has a fully owned software engineering subsidiary in the Philippines.

CSAM has established itself as a leading Nordic niche player in the specialized eHealth market, with a unique blend of best-in-class innovative technology and outstanding human skills. Backed by strong financial owners, CSAM aspires to achieve continued growth both organically and through selected mergers and acquisitions.

For more information, visit csamhealth.com.

About Databyrån AB

Databyrån AB is based in Sweden and serves healthcare professionals across the Nordics. Founded in 1965, the company is a leader in software development for transfusion medicine, developing strong relationships with its users. Databyrån AB’s clients span the fields of transfusion medicine, immunology, transplantation immunology, and https://buyphentermineonlinetoday.com/.

For more information, visit databyran.se and prosang.com.

For more information, please contact:

Sverre Flatby
Group CEO, CSAM Health AS
+47 9159 9159
sverre.flatby@csamhealth.com

Daniel Wiman
Chairman, Databyrån AB
+46 70-482 77 57
daniel.wiman@databyran.se

 

Einar Bonnevie
Chief Financial Officer
Categories

Related News

Omda AS: Key information relating to proposed cash dividend
Read More
Omda AS – Notice of ordinary general meeting
Read More
Omda delivers 12% growth and increased profitability in 2023.
Read More
Exploring challenges and trends in modern blood management
Read More

Get in touch

Please enable JavaScript in your browser to complete this form.
Name
Helen Døcker
Chief Marketing & Communications Officer
helen.docker@omda.com
She is based in the company’s headquarters in Oslo, Norway.

Join our conversation to build a safer and healthier world.